Search

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

To investigate the therapeutic effect of Tongbi capsule on rheumatoid arthritis (RA) and its influence on microcirculation index, matrix metalloproteinase-1 (MMP-1) and serum matrix metalloproteinase-3 (MMP-3). 90 patients with RA admitted to our hospital from January 2016 to September 2018 were selected, they were divided into study group (n=45), control group (n=45) according to the random number table method. The control group was treated with leflunomide and methotrexate. The study group was treated with Tongbi capsule on the basis of the control group. The therapeutic effect, microcirculation indexes before and after treatment [Vascular resistance index (RI), diastolic peak velocity (EDV) and systolic peak velocity (PSV)], MMP-1, MMP-3, Rheumatoid factor titer (RF), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), antistreptolysin "O" (ASO) of the two groups were compared, adverse reactions were recorded. The total clinical effective rate of the study group was higher than that of the control group (P<0.05). The RI, MMP-1, MMP-3, CRP, RF, ESR and ASO of the two groups decreased after 4 months of treatment, and the study group was lower than the control group (P<0.05); EDV and PSV increased, and the study group was higher than the control group (P<0.05). There was no difference in the incidence of adverse reactions between the two groups (P>0.05). on the basis of routine treatment, Tongbi capsule can effectively alleviate RA, improve microcirculation, reduce the levels of MMP-3 and MMP-1 in serum, and the drug safety is good. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective: To explore the effects of H3K9me3 on rat thoracic aortic smooth muscle A7r5 cell proliferation induced by high glucose, and to study its underlying mechanism. Methods: Under the high glucose condition, MTT assays were applied to observe the effects of different concentrations of H3K9 methyltransferase SUV39H1 specific inhibitor Chaetocin (0, 10, 25, 50, 75, 100 nmol/L) and 50 nmol/L Chaetocin at different time points (24, 48, 72 h, 5 d)on rat thoracic aortic muscle A7r5 cell proliferation, respectively. Western bolt was used to explore the protein expression of H3K9me3 and p53 after 50 nmol/L Chaetocin incubating A7r5 cells for 72 h. Results: Chaetocin can significantly suppressed A7r5 cell proliferation induced by high glucose in a concentration- and time- dependent manner. Compared with normal concentration of glucose, Chaetocin significantly inhibited the up-regulated expression of H3K9me3 and increased the down-regulated expression of p53 induced by high glucose in A7r5 cells (P<0.05). Conclusions: Down-regulated p53 can enhance the proliferation of rat thoracic aortic muscle cell induced by high glucose via H3K9me3, while H3K9 methyltransferase inhibitor Chaetocin can suppressed this process, which provides a new insight for the treatment of diabetic macroangiopathy. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)